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Abstract  
 
Longitudinal strain (LS) has been shown to be predictive of outcome in hypertrophic 
cardiomyopathy (HCM). Percent predicted peak oxygen uptake (ppVO2), among other 
cardiopulmonary exercise testing (CPX) metrics, is a very strong predictor of prognosis. 
However, there has been limited investigation into the combination of LS and CPX metrics. 
This study sought to determine how LS contributes to parameters of exercise performance 
for prognosis in HCM. One hundred and thirty-one consecutive patients with HCM who 
underwent CPX with simultaneous stress echocardiography were included. Global, septal 
and lateral LS were assessed at rest and stress. Eighty matched individuals were used as 
controls. Patients were followed for the composite endpoint of death and worsening heart 
failure (HF). All absolute LS components were lower in patients with HCM compared to 
controls (global 14.3±4.0% vs 18.8±2.2%, p<0.001; septal 11.9±4.9% vs 17.9±2.7%, p<0.001; 
lateral 16.0±4.7% vs 19.4±3.1%, p=0.001). Global strain reserve was also reduced among 
patients with HCM (13±5% vs 19±8%, p=0.002). Over a median follow-up of 56 months (IQR 
14-69), the composite endpoint occurred in 53 patients. Global LS was predictive of 
outcome on univariate analysis (0.55[0.41-0.74], p<0.001). When combined with CPX 
metrics, lateral LS was the only independent predictor of outcome among strain variables 
along with indexed left atrial volume (LAVI) and ppVO2. The worst outcomes were observed 
for patients with lateral LS<16.1%, LAVI>52ml/m2 and ppVO2<80%. Patients with HCM have 
decreased strain reserve when compared to controls. The combination of lateral LS, LAVI 
and ppVO2 presents a simple model for outcome prediction.  
Keywords: Hypertrophic Cardiomyopathy, Cardiopulmonary exercise testing, Contractile 
Reserve, Deformation imaging 
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Introduction  
Hypertrophic Cardiomyopathy (HC) is an inherited disease characterized by a variable 
clinical course. Advances in primary prevention of sudden cardiac death (SCD) have 
simultaneously improved arrhythmic outcomes and increased the impact of chronic heart 
failure (HF)-related outcomes.1, 2 Among predictors of outcome in HC, magnitude of 
hypertrophy, left atrial volume, left ventricular outflow tract (LVOT) obstruction, 
hypotensive response to exercise and peak oxygen uptake (peak VO2) have emerged as the 
strongest.3-9 Myocardial fibrosis, myocyte disarray and altered sarcomere kinetics typically 
affect myocardial mechanics in the early phases of HC with preserved LV ejection fraction 
(LVEF) which has led to an interest in strain echocardiography.10 Longitudinal strain (LS), has 
demonstrated strong predictive value in myocardial diseases, including HC, which has 
recently been associated with a higher risk of adverse cardiovascular events.4, 11, 12 Regional 
components of LS and augmentation with exercise (contractile reserve) has not been well 
studied in HC.13 Moreover, there has been limited investigation into integration of CPX with 
strain echocardiography.14, 15 The current study explores the implication of the 
complementarity of CPX and echocardiography in risk modeling of HF events in HC. 
Methods 
In 2007, Stanford University established the Stanford Exercise Testing (SET) Registry, 
where patients who have obtained simultaneous stress echocardiography with CPX are 
included. For this study, approved by the University’s Institutional Review Board, we 
screened the SET registry from January 1st 2007 and January 1st 2012. Patients were 
included if they had a diagnosis of HC as defined by  (a) the presence of significant LV 
hypertrophy (end-diastolic wall thickness >15 mm in M-mode or 2D echocardiography) in 
the absence of other etiologies, or (b) wall thickness between 13 and 15 mm in the presence 
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of abnormal electrocardiography or family history of inherited cardiomyopathy and (c) had 
simultaneous CPX and echocardiogram.3 Patients were not included if they (a) had 
documented prolonged systemic hypertension, (b) previous alcohol ablation or septal 
myectomy, (c) poor image quality on either rest or stress echocardiography or (d) less than 
12 months follow up. Data were collected during the outpatient visit on the day of 
CPX/echocardiography. For comparison to the HC cohort, 80 contemporary participants 
who underwent stress echocardiogram and had (a) normal resting LVEF, (b) normal rest and 
stress wall motion and (c) no hemodynamically significant valvular disease were included. 16 
These controls were excluded if they had (a) left ventricular hypertrophy, (b) significant ST 
changes or arrhythmias, (c) exaggerated blood pressure response to exercise or (d) 
functional capacity less than 90% of normal.17  The primary end-point for outcome analysis 
was a composite of death and worsening HF  (cardiac transplantation, NYHA III-IV class 
progression leading to hospitalization). Outcomes were assessed by two cardiologists 
independently using computerized medical records.  
All patients underwent baseline resting echocardiography (iE33; Philips Medical 
Imaging, Eindhoven, the Netherlands). Stress images were acquired immediately post-
exercise, with the apical 4 chamber acquired first and thus used to calculate measures of 
longitudinal strain. Images were analyzed by the Stanford Cardiovascular Institute Clinical 
Biomarker and Phenotype Core Laboratory on Xcelera workstations in accordance with 
published guidelines from the American Society of Echocardiography (ASE).16, 18 Two 
experienced cardiologists independently analyzed the acquired images, and were blinded to 
the results of the CPX metrics and clinical outcomes. LVEF was calculated by manual 
contouring of apical 4-chamber imaging. GLS was calculated on manual tracings of the mid-
wall with the Lagrangian Strain Formula [(L1 - L0)/L0] x 100.19 Lateral strain and septal strain 
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were calculated with the same technique, however, the mid-wall length was assessed from 
the lateral annulus to apex and mitral annulus to apex, respectively (Figure 1). We present 
strain data in absolute values.4, 11 With tissue Doppler imaging, we used peak myocardial 
early diastolic velocity at the lateral mitral annulus and the assessment of trans-mitral to 
tissue Doppler imaging early diastolic velocity ratio (E/e’). Left atrial volume was calculated 
in the apical 4-chamber view at end systole then indexed to body surface area (LAVI). 
Systolic left ventricular gradient was quantified using the continuous-Doppler technique. A 
peak gradient >30mmHg at rest was considered significant.7 Mitral regurgitation severity 
was assessed according to current guidelines.20 Regarding measurement of reserve, 
absolute change (peak–rest) and relative change [(peak-rest)/peak) x 100] were calculated 
for LVEF and each component of LS. 
Symptom-limited CPX was performed on a treadmill (Trackmaster by FullVision, 
Kansas, USA) with an integrated metabolic cart (Quark CPET, CosMed USA Inc, Concord, CA, 
USA), using breath-by-breath data capture and analysis with an individualized RAMP 
treadmill protocol.21 Minute ventilation (VE), oxygen uptake (VO2), carbon dioxide 
production (VCO2), and other CPX variables were acquired breath by breath and averaged 
over 20 second intervals for interpretation. VE and VCO2 responses throughout exercise 
were used to calculate the VE/VCO2 slope via least squares linear regression.
22 To correct for 
differences in age and gender, the ppVO2 was calculated using the Wasserman formula.
23 
The achievement of a respiratory exchange ratio (VCO/VO2) of 1.05 and perceived exertion 
>16, (6-20 scale) were used to determine peak effort. A continuous 12-lead 
electrocardiogram was obtained with recordings at rest, each minute during exercise and 
for at least five minutes during recovery from exercise. 
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Baseline characteristics were expressed as mean ± SD for parametrically distributed 
values and as median and IQR for non-parametrically distributed variables. Categorical 
variables are presented as frequencies and/or percentages. To investigate differences 
between the HC cohort and the controls, independent-sample t-tests were performed. 
Linear regression analysis was used to determine independent associations between 
echocardiographic and CPX variables. The associations between clinical, echocardiographic, 
CPX variables and outcome were analyzed using Cox proportional hazards models. Variables 
significantly associated with the composite outcome from univariate analysis were selected 
for entry into a multivariate model and corrected age and gender. Multivariate models were 
performed using stepwise elimination in separate blocks (echocardiographic with global and 
regional strain and CPX variables). Cumulative rates of the composite endpoint as a function 
of time were obtained by the Kaplan-Meier method and compared using the log-rank test. 
Cut-offs were derived from receiver operating characteristic (ROC) curves of our cohort and 
compared to current population data. Inter-observer variability was quantified for 
echocardiographic measurements using mean differences intra class correlation coefficient 
and the Bland-Altman method (bias) (Supplementary Table 1). Analyses were performed 
using MedCalc version 15.8 and RStudio Version 1.0.136 – © 2009-2016 RStudio, Inc. 
Results 
One hundred and thirty-one consecutive patients were enrolled with baseline 
characteristics summarized in Table 1. Baseline demographics of controls are provided in 
Supplementary Table 2.  Complete echocardiographic assessment was available in all 
patients at rest. Of the HC patients 7 (6%) had reduced image quality with stress that 
precluded accurate LS evaluation. Table 2 and Figure 2 show the values of rest and post-
exercise septal, lateral and global LS with HC patients having significant lower values for all 
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components of strain (p<0.001). Exercise was associated with a significant increase in LS, 
both in the HC cohort and controls (p<0.001) however, relative strain reserve was reduced 
in patients with HC (13 ± 5% vs 19 ± 8%, p =0.002).  
There was no correlation between septal wall thickness and septal LS (r=0.12, 
p=0.25) or posterior wall thickness and lateral LS (r=0.01, p=0.90). There was a moderate 
correlation between septal and lateral LS (r=0.51, p<0.001). LS metrics showed weak 
correlations (Supplementary Figure 1) with other echocardiographic variables and CPX 
metrics. Of the echocardiographic variables, e’ showed the highest correlation with ppVO2 
(r=0.31, p<0.001). 
During a median follow-up of 56 months (IQR 15-68) the composite primary 
outcome occurred in 53 patients (6 deaths and 47 worsening HF). Parameters significantly 
associated with outcome at univariate analysis (Table 3), were placed in each of our 
multivariate models (Table 4). When combined with established echocardiographic metrics, 
of strain variables, only lateral LS was independently associated with the primary outcome. 
While peak strain was associated with outcome at univariate analysis these variables were 
not retain when combined with rest parameters in our multivariate models.  Among the CPX 
variables, only ppVO2 was statistically significantly associated with the primary end-point, 
whereas a borderline association was observed for the VE/VCO2 slope. A single multivariate 
model incorporating lateral LS along with ppVO2 and LAVI was found to be predictive of the 
primary outcome (x2 = 39, p <0.001). Using the variables independently associated with 
outcome, those patients with LAVI > 52ml/m2, lateral LS < 16.1% and ppVO2 < 80% had a 
poorer prognosis (p<0.001). As seen in Figure 3 the presence of one, two, and three risk 
factors each increased risk of the composite outcome (log rank p<0.001).  When events in 
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the first year of follow up were censored, the differences in outcome among patients with 
these risk factors remained (Supplementary Figure 1).  
Discussion 
The main findings of this paper are threefold. First, we show that LS reserve is 
significantly reduced in patients with HC and is only weakly associated with measures of 
exercise performance. Second, we validate recent findings that show LS is a major predictor 
of HF outcomes in HC patients. Third, our findings highlight that a simple combination of LS, 
LAVI and ppVO2 may discriminate HF and survival outcomes in HC patients.  
Contractile reserve has been poorly investigated in HC, partially due to patients often 
having a supranormal LVEF at rest and the LVOT flow being distorted by obstruction. 
Deformation imaging in HC has been investigated in recent studies, demonstrating a close 
relationship to clinical outcome.4, 24, 25 Multiple pathophysiological mechanisms including 
hypertrophy, microvascular ischemia, myocardial fibrosis and sarcomere dysfunction may 
underlie reduction in GLS and ultimately contribute to overt HF.10, 26 Our study of 131 
patients has shown that high-quality assessment of GLS at peak exercise intensities is 
feasible. We were also able to assess reserve through the relative difference in strain, which 
appeared to be reduced when compared to controls. This validates the findings of Schnell et 
al. who in in a small cohort HC patients (n=25) found an absolute mean change in GLS of 1.9 
(relative change 11%) during exercise testing.27 Resting measures of systolic function and 
reserve in our cohort, as with previous studies in HF only mildly correlated with measures of 
exercise performance, indicating we should consider them complementary in clinical 
assessment or prognostication.  
Despite the underlying pathophysiology, HC is often asymmetric, which led us to 
challenge the use of global metrics. The current study took the preferred measure of systolic 
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function in HC (LS) and explored the benefit of regional strain analysis. It appears that 
regional LS assessment at rest and immediately post exercise is feasible and reproducible in 
individuals with and without HC. The lower absolute mean value and standard deviation of 
septal strain in the HC groups reflects the predominance of septal involvement. These 
characteristics should make septal LS useful as a diagnostic marker, however, not 
necessarily as prognosticator for HF outcome. In our cohort, patients with absolute lateral 
LS <16.1% had a significantly higher rate of adverse events. This may be related to relative 
homogeneity of septal hypertrophy and decreased septal LS even among different 
morphologies of HC. Considering lateral LS and global LS had a similar impact on outcome, 
this might suggest the weight of global LS in influencing prognosis in HC might be driven by 
the lateral component. Further larger studies to evaluate change in lateral LS in HC over 
time will be needed to further support this hypothesis. 
Outcome prediction in HC is complex due to the heterogeneity across recent trials. 
The focus of the current study is on HF outcome, not arrhythmic outcome. Doppler 
assessment of LVOT gradient has been used to risk stratify patients with HC.7 However, the 
interpretation of gradients, particularly during exercise testing, can be complex and prone 
to variability. This has been complicated by the findings of a recent study by Desai et al, 
which showed that asymptomatic patients with greater than 100% ppVO2 had excellent 
outcomes regardless of the degree of LVOT obstruction.28 A higher ppVO2 has also been 
associated with improved outcomes in symptomatic patients (NYHA class II and NYHA III).29  
Our findings are consistent with these recent studies demonstrating that ppVO2 is 
independently and strongly associated with HF outcome, emphasizing the important 
contribution exercise capacity has to the prognosis of patients with HC. The clinical 
implication among the growing body of evidence in HC patients and exercise is that exercise 
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testing with gas analysis (where available) should be strongly considered. Left atrial volume 
also been a consistent marked of outcome in HC.5, 6 It is reassuring  that it performed well 
with regard to outcome in our cohort. One of the important contributions of the current 
study is that a simple combination of complementary variables may capture an important 
component of risk in HC. Our exploratory data suggested that (a) satisfactory exercise 
performance ppVO2, (b) preserved lateral LS and (c) modest or absence of left atrial 
enlargement appears to have the most favourable prognosis.  
The present study should be interpreted in the context of the methodological 
limitations. We did not use automated computationally-derived LS; our lab has previously 
shown good correlation of automated and manual assessment of strain and there was 
excellent inter-reader variability in measures of LVEF and strain.30 This is a single speciality 
centre experience, which introduces an unavoidable selection bias with a likely over-
representation of patients with advanced disease compared to other clinics. However, when 
events were censored during the first year of follow up, our outcome models remained 
unchanged. Furthermore, patients who did not undergo CPX as part their initial evaluation 
were excluded; however, this represented <5% of our cohort. Finally regarding outcome 
analyses, while the lower threshold for ppVO2 has been previously described, it was 
necessary to derive the lower threshold for lateral LS from our dataset. Also, though we had 
a reasonable length of follow up, we had limited number of total events (n=53) and so these 
findings should be viewed as preliminary. In conclusion, strain imaging, both peak and 
regional appears feasible, with HC patients having reduced absolute values and strain 
reserve.  When integrating strain and exercise testing into risk modelling, combining a 
structural (LAVi), functional (LS) and exercise (ppVO2) metric may present a simple model 
for HF outcome prediction.  
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Figure 1- Calculation of longitudinal strain. Longitudinal strain (LS) was calculated from the 
four- chamber view on manual tracings of the mid wall with the formula for Langrangian 
Strain. Lateral and septal LS were calculated by the same technique, however, mid wall 
length was assessed from either septal or lateral mitral annulus to the apex.  
 
Figure 2 – Dynamic changes in longitudinal strain.  LS is shown in controls, n=80 (left) and 
patients with HC, n=124 (right) at rest and immediately post exercise.  
 
Figure 3. Kaplan Meier Curve for risk factor score. Patients are stratified according to LAVI 
(>52ml/m2), lateral LS (<16.1%) and ppVO2 (<80%). Group 1 represents 0 risk factors, group 
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2, 1 risk factor, group 3, 2 risk factors and group 4, 3 risk factors. Each additional factor was 
associated with a significant decrement in prognosis, log rank test p<0.001. 
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Table 1 – Baseline Characteristics  
Variable  Patient Cohort (n=131) 
Age (years) 52 ± 13 
Male  83(63%) 
Body mass index (kg/m2) 29 ± 6 
Family history of sudden cardiac death 36(28%) 
Syncope  34(26%) 
Non sustained ventricular tachycardia   40(30%) 
Atrial Fibrillation  24(18%) 
Resting heart rate (bpm) 67 ± 12 
New York Heart Association Class III  27(21%) 
Systolic blood pressure  (mm Hg) 119 ± 19 
Cardiopulmonary exercise testing  
 Peak heart (bpm) 138±29 
Peak systolic blood pressure (mmHg) 158±27 
Drop in systolic blood pressure with exercise  5 (4%) 
Respiratory exchange ratio  1.10 ± 0.09 
External Workload (METS)  10.3 ± 4.8 
Maximal oxygen consumption (ml/kg/min)  26 ± 11 
Percent predicted maximal oxygen consumption (<80%) 53 (40%) 
Ventilation and carbon dioxide production slope  (>32) 26 (20%) 
Therapy  
 Beta blocker  81(62%) 
Calcium channel blocker  39(30%) 
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Dysopiramide (%) 5(4%) 
ACE Inhibitor or ARB (%) 35(28%) 
Diuretics (%) 8(6%) 
Automatic implantable cardioverter-defibrillator 51(39%) 
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Table 2 – Echocardiographic Measures 
Variable  Patient Cohort 
LV interventricular septum thickness (mm) 18 ± 5 
LV posterior wall thickness (mm) 11 ± 3 
LV end diastolic volume (ml/m2) 86 ± 29 
LV end systolic volume (ml/m2) 28 ± 17 
LV ejection fraction (%) 64 ± 9  
E/e` 12.0 ± 6.7 
e` (cm/sec) 8 ± 3 
Left atrial volume index (ml/m2) 44 ± 17 
Mitral regurgitation  ≥2+  48 (37%) 
LV gradient > 30 mmHg at rest  41 (31%) 
Left ventricular outflow tract gradient post stress (mmHg) 57 ± 52 
Strain assessment (rest n=131, stress n=124)   
Rest global longitudinal strain (%) 14.3 ± 3.9  
Rest septal longitudinal strain  (%) 12.3 ± 4.4  
Rest lateral longitudinal strain (%) 16.1 ± 4.6  
Stress global longitudinal strain (%) 16.8 ± 4.2 
Stress septal longitudinal strain  (%) 14.5 ± 4.6 
Stress lateral longitudinal strain (%) 18.8 ± 5.4 
Relative change global longitudinal strain (%) 13 ± 15 
Relative change septal longitudinal strain (%) 13 ± 26 
Relative change lateral longitudinal strain (%) 12 ± 22 
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Table 3 - Univariate predictors of primary outcome 
Variable HR 95% CI p value  
Rest Echocardiography (n=131)  
       LV interventricular septum thickness  (mm) 1.15 [1.02-1.31] 
[1.00-1.30] 
[0.95-1.38] 
[1.37-2.10] 
[1.20-1.85] 
[0.35-0.77] 
[1.21-2.03] 
[0.41-0.74] 
[0.37-0.67] 
[0.56-0.99] 
0.026 
LV posterior wall thickness (mm) 1.14 0.059 
LV end systolic volume  (ml/m2) 1.15 0.153 
Left atrial volume index (ml/m2) 1.70 <0.001 
E/e` 1.49 <0.001 
e` (cm/sec) 0.52 0.004 
Left ventricular outflow gradient (>30mmHg) 1.57 0.001 
Global longitudinal strain  (%) 0.55 <0.001 
Lateral longitudinal strain   (%) 0.50 <0.001 
Septal longitudinal strain  (%) 0.75 0.043 
Stress Echocardiography (n=124)   
       Strain reserve  0.94 [0.69-1.27] 
[0.42-0.74] 
[0.42-0.75] 
[0.49-0.91] 
0.700 
Global longitudinal strain   (%) 0.56 <0.001 
Lateral longitudinal strain   (%) 0.56 <0.001 
Septal longitudinal strain  (%) 0.66 0.010 
CPX (n=131) 
       Peak heart rate (bpm) 0.70 [0.42-0.75] 
[0.44-0.76] 
[0.41-0.75] 
[0.42-0.76] 
0.026 
Peak systolic blood pressure (mmHg) 0.62 0.002 
External workload (METS)  0.55 <0.001 
Maximum oxygen consumption (ml/kg/min) 0.57 <0.001 
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Percent predicted maximum oxygen consumption (%) 0.59 [0.46-0.76] 
[1.25-1.96] 
<0.001 
Ventilation and carbon dioxide production slope  1.57 <0.001 
Hazard ratios adjusted for standard deviation. 
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Table 4 – Multivariate Cox Regression Analysis for primary outcome. 
 
                                       Global 
 
                          Regional 
    HR 95% CI 
p 
value    HR 95% CI 
p 
value  
Rest 
Left atrial volume index 
1.4
7 
1.12-
1.94 0.005 Left atrial volume index 
1.5
3 
1.18-
1.99 0.001 
e` 
0.5
9 
0.39-
0.93 0.023 e` 
0.6
3 
0.41-
0.99 0.047 
Global longitudinal strain 
0.7
0 
0.49-
1.03 0.072 Lateral Longitudinal strain  
0.6
1 
0.42-
0.89 0.009 
      x2=23       x2=27 
CPX 
Percent Predicted maximal oxygen 
consumption 
0.5
6 
0.45-
0.78 0.001         
VE/VCO2 
1.3
1 
1.00-
1.70 0.500 
          x2=27         
Integrate
d Model  
Left atrial volume index  
1.4
4 
1.11-
1.87 0.006 Left atrial volume index 
1.5
1 
1.15-
1.99 0.008 
Global longitudinal strain 
1.2
7 
0.94-
1.73 0.119 Lateral longitudinal strain  0.9 
0.84-
0.96 0.020 
Percent Predicted maximal oxygen 
consumption 
0.6
2 
0.44-
0.88 0.007 
Percent Predicted maximal oxygen 
consumption 
0.6
4 
0.44-
0.94 0.040 
      x2=34       x2=39 
All models are adjusted for age and gender. Hazard ratios adjusted for standard deviation. 
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